Archive: Company News
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
– Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced the appointment of Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development.
Thermosome Establishes High-Profile Clinical Advisory Board
– Leveraging the transformative potential of TSL-based tumor targeting
– Supporting the progress of Thermosome’s clinical candidate THE001
Thermosome, a drug development company specializing in targeted tumor therapies, today announced the formation of a Clinical Advisory Board to support the advancement of its lead compound THE001 through clinical development.
The board consists of leading international cancer specialists in the fields of soft tissue sarcoma and bladder cancer, experts in hyperthermia, immunotherapy, and surgery/neoadjuvant therapy: Read more…
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
— Key milestone for novel, resorbable breast / pectus reconstruction implants
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today reported encouraging one-year follow-up data of its breast and pectus excavatum scaffolds.
Both pectus and breast implants demonstrated a very good safety profile, were very well accepted by the surgeons and patients expressed high satisfaction and reported an improvement in quality of life. A significant improvement in pain scores was observed in breast reconstruction patients with prior silicone implants. All patients´ breasts maintained their shape and volume after surgery. Read more…
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
— Ongoing Phase IIb study expands to arm B
— 5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantation
— Second closing of Series A round
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. Read more…